Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam

• DOI: 10.31557/apjcp.2021.22.5.1581
• Publication Date: 2021-05-28T17:20:05Z
• Authors: Thanh Vu; Hoa Nguyen; Linh Dao; Chi Duong; Cao Nguyen; Tuyet Doan; Hang Nguyen; Hung Hoang; Dung Dinh; Giang Le; Thanh Vu; Minh Truong; Long Nguyen
• Keywords: Tolerability; Afatinib

Background: We aimed to evaluate the effectiveness and tolerability of Afatinib as first-line treatment advanced epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC) in a real-world setting. Patients methods: This is retrospective study Vietnamese patients with EGFR-mutant NSCLC treated afatinib at National Cancer Hospital from 1st January 2018 31st October 2020. Patients’ demographic, clinical data were captured. Objective response rate (ORR), disease control (DCR), time failure (TTF) evaluated. used Kaplan-Meier curve log-rank test for survival, Cox regression model multivariate analysis. Results: A total 44 included. Common EGFR mutations (Del 19/L858R) detected 61% patients. Fifty percent uncommon had compound G719X, L861Q S768I. The ORR was 75% while DCR 98%. median TTF 12.3 months (95% CI: 7.2-17.3); mTTFs 10.8 common (p = 0.001), respectively, 14.0 7.5 Del 19 L858R 0.067), respectively. 30 mg once daily most starting (77%) maintenance (64%) doses. dose vs 40 0.256), Diarrhea, skin rash, paronychia fatigue observed 32%, 30%, 25% 9%, There no grade 4 toxicity except three 3 paronychia. Conclusions: First-line beneficial good prolonged manageable adverse event profile. Baseline brain metastasis status doses do not significantly impact TTF.